Results 11 to 20 of about 121,959 (273)

A Method to Detect the Binding of Hyper-Glycosylated Fragment Crystallizable (Fc) Region of Human IgG1 to Glycan Receptors [PDF]

Methods in molecular biology, 2018
Engineering the fragment crystallizable (Fc) of human IgG can bring improved effector functions to monoclonal antibodies and Fc-fusion-based medicines and vaccines. Such Fc-effector functions are largely controlled by posttranslational modifications (PTMs) within the Fc, including the addition of glycans that introduce structural and functional ...
Patricia A. Blundell, Richard J. Pleass
semanticscholar   +5 more sources

Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions

Nature Biomedical Engineering, 2022
Short half-lives in circulation and poor transport across the blood–brain barrier limit the utility of cytokines and growth factors acting as receptor agonists.
Katsuya Sakai, Nozomi Sugano-Nakamura, E. Mihara, N. Rojas-Chaverra, Sayako Watanabe, Hiroki Sato, R. Imamura, D. Voon, Itsuki Sakai, C. Yamasaki, C. Tateno, Mikihiro Shibata, H. Suga, J. Takagi, Kunio Matsumoto   +14 more
semanticscholar   +3 more sources

The Neonatal Fc Receptor (FcRn): A Misnomer?

Frontiers in Immunology, 2019
Antibodies are essential components of an adaptive immune response. Immunoglobulin G (IgG) is the most common type of antibody found in circulation and extracellular fluids.
Michal Pyzik, Kine M. K. Sand, Kine M. K. Sand, Jonathan J. Hubbard, Jonathan J. Hubbard, Jan Terje Andersen, Jan Terje Andersen, Inger Sandlie, Richard S. Blumberg, Richard S. Blumberg   +9 more
doaj   +2 more sources

Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

Human Vaccines & Immunotherapeutics
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) require additional treatments, especially those not eligible or not responding to high dose cytotoxic chemotherapy and stem cell transplantation.
Maria Cristina Pirosa, Anastasios Stathis, Emanuele Zucca   +2 more
doaj   +2 more sources

Pre-Clinical Studies of a Novel Bispecific Fusion Protein Targeting C3b and VEGF in Neovascular and Nonexudative AMD Models. [PDF]

Ophthalmol Ther
Introduction KNP-301 is a bi-specific fragment crystallizable region (Fc) fusion protein, which inhibits both C3b and vascular endothelial growth factor (VEGF) simultaneously for patients with late-stage age-related macular degeneration (AMD).
Lee Y, Kim D, Chung PED, Lee M, Kim N, Chang J, Lee BC.   +6 more
europepmc   +2 more sources

N-linked Fc glycosylation is not required for IgG-B-cell receptor function in a GC-derived B-cell line

Nature Communications
IgG secreted by B cells carry asparagine N(297)-linked glycans in the fragment crystallizable (Fc) region. Changes in Fc glycosylation are related to health or disease and are functionally relevant, as IgG without Fc glycans cannot bind to Fcɣ receptors ...
Theresa Kissel, Veerle F. A. M. Derksen, Arthur E. H. Bentlage, Carolien Koeleman, Lise Hafkenscheid, Diane van der Woude, Manfred Wuhrer, Gestur Vidarsson, René E. M. Toes   +8 more
doaj   +2 more sources

IGLV3-21^R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia

Haematologica
We previously used a disease-specific B cell receptor (BCR) point mutation (IGLV3-21R110) for selective targeting of a high-risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR) T cells.
Claudia Fischer, Shih-Shih Chen, Johanna Nimmerfroh, Anne Eugster, Simon Stücheli, Christoph Schultheiß, Corinne Widmer, Dominik Heim, Benjamin Kasenda, Jakob Passweg, Sebastian Kobold, Lukas Egli, Nicolò Coianiz, Obinna Chijioke, Nicholas Chiorazzi, Marie Follo, Heinz Läubli, Matthias Peipp, Mascha Binder   +18 more
doaj   +2 more sources

Rapid In Vivo Screening of Monoclonal Antibody Cocktails Using Hydrodynamic Delivery of DNA-Encoded Modified Antibodies [PDF]

Biomedicines
Background: Monoclonal antibodies (mAbs) are potent treatment options for infectious diseases. The rapid isolation and in vivo validation of therapeutic mAb candidates, including mAb cocktails, are essential to combat novel or rapidly mutating pathogens.
Hugues Fausther-Bovendo, George (Giorgi) Babuadze, Teodora Ivanciuc, Birte Kalveram, Yue Qu, Jihae Choi, Allison McGeer, Mario Ostrowski, Samira Mubareka, Ami Patel, Roberto P. Garofalo, Robert Kozak, Gary P. Kobinger   +12 more
doaj   +2 more sources

Rheumatoid Factor: Diagnostic and Prognostic Performance and Therapeutic Implications in Rheumatoid Arthritis. [PDF]

J Clin Med
Rheumatoid factor (RF) is the first autoantibody identified in rheumatoid arthritis (RA) which targets the fragment crystallizable (Fc) region of immunoglobulin (Ig) G.
Togashi T, Ishihara R, Watanabe R, Shiomi M, Yano Y, Fujisawa Y, Katsushima M, Fukumoto K, Yamada S, Hashimoto M.   +9 more
europepmc   +2 more sources

Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV

The Journal of Clinical Investigation
The function of the spike protein N terminal domain (NTD) in coronavirus (CoV) infections is poorly understood. However, some rare antibodies that target the SARS-CoV-2 NTD potently neutralize the virus.
Naveenchandra Suryadevara, Nurgun Kose, Sandhya Bangaru, Elad Binshtein, Jennifer Munt, David R. Martinez, Alexandra Schäfer, Luke Myers, Trevor D. Scobey, Robert H. Carnahan, Andrew B. Ward, Ralph S. Baric, James E. Crowe Jr   +12 more
doaj   +2 more sources